Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Patent
1993-03-16
1997-03-25
Cunningham, Thomas M.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
4241841, 4241931, 514 2, 514 12, 514 16, 530300, 530324, 530328, 530868, A61K 3800, C07K 14725
Patent
active
056141920
ABSTRACT:
Peptides and pharmaceutical compositions comprising immunogenic peptides of a marker T cell receptor (TCR) characteristic of an immune-related disease, capable of preventing, suppressing, or treating the disease, are disclosed. In a preferred embodiment, the amino acid sequence of the peptide corresponds to at least part of the second complementarity determining region (CDR2) of the TCR. Antibodies and/or T cells immunologically reactive to the TCR peptide capable of preventing, suppressing, or treating an immune-related disease by passive transfer are also disclosed.
REFERENCES:
patent: 4634590 (1987-01-01), Cohen et al.
patent: 4716038 (1987-12-01), Stanford et al.
patent: 4845026 (1989-07-01), Kung et al.
patent: 4873190 (1989-10-01), Saito et al.
patent: 4874845 (1989-10-01), Saito et al.
patent: 4886743 (1989-12-01), Hood et al.
patent: 5114721 (1992-05-01), Cohen et al.
patent: 5316925 (1994-05-01), Davis et al.
patent: 5340921 (1994-08-01), Brenner et al.
patent: 5436319 (1995-07-01), Kung et al.
Desquenne-Clark, L. et al., P.N.A.S. (USA) 88:7219-7223 (Aug. 1991), "T-Cell Receptor Peptide Immunization Leads to Enhanced and Chronic Experimental Allergic Encephalomyeitis".
Esch, T. et al., Critical Reviews in Immunology 11(5): 249-264 (1992), "Observations Legends Conjectures Concerning Restricted T-cell Receptor Usage and Autoimmune Disease".
Howell, M.D. et al., Science 246:688-670 (1989).
Janeway, C.A., Nature 341:482-483 (1989).
Happ, M.P. et al., J. Neuroimmunol. 19:191-204 (1988).
Hashim, G., et al., "Suppression . . . peptide," FASEB Journal, vol. 4, No. 7, 26 Apr. 1990, p. A2023.
Paul, W. F. (ed), Fundamental Immunology, 3rd edition (1993), pp. 679-685 (Immunological Tolerance), 903-915 (Immunosuppression), and 1033-1095 (Autoimmunity and Autoimmune Diseases).
Urban, J. L., et al., Cell 54:577-592 (Aug 12, 1988), "Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy".
Vandenbark, A. A., et al., Nature 341:541-544 (12 Oct. 1989), "Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis".
Wraith, D. C., et al. Cell 57:709-715 (Jun. 2, 1989), "T cell recognition as the target for immune intervention in autoimmune disease".
Acha-Orbea, et al., Cell 54:263-273 (Jul. 15, 1988), "Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis specific immune intervention".
Ben-Nun, A., et al., Nature 292:60-61 (1981), "Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein".
Brostoff, S., Immunol. Ser. 59:203-218 (1993), "Vaccination with T-cell receptor peptides".
Holoshitz, J., et al., J. Immunol. 131(6):2810-2813 (1983), "Autoimmune encephalomyelitis (EAE) mediated or prevented by T lymphocyte lines directed against diverse antigenic determinants of myelin basic protein. Vaccination is determinant specific".
Howell, M. D., et al., Science 246:668-670 (1989), "Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides".
Kappler, J. W., et al., Cell 49:263-271 (Apr. 24, 1987), "A T cell receptor V.beta. segment that imparts reactivity to a class II major histocompatibility complex product".
Hafler, D. A.., Immunology Today 17(4): 152-159, "TCR usage in human and experimental demyelinating disease". Apr. 1996.
Steinman, L., Annals N. Y. Acad. Sci. 636: 147-153, "Prospects for immunotherapy directed to the T cell receptor in human autoimmune disease". 1991.
Vandenbark, A. A. et al., J. Neurosci. Res. 43:391-402, "T cell receptor peptides in treatment of autoimmune disease: rationale and potential". 1996.
Brostoff, S., "The development and use of T cell receptor peptide vaccines" in Immunobiology of Proteins and Peptides VIII (M. Z. Atassi, ed.), Plenum Press, New York. 1995.
Brostoff, S. W. et al., Annals of the New York Academy of Sciences, vol. 636, pp. 71-78. Dec. 1991.
Brostoff, S. in Monoclonal Anitbodies and Peptide Therapy in Autoimmune Diseases, J. Bach, editor, Chapter 13, pp. 203-218, "Vaccination with T cell receptor peptides". 1993.
Davis, M. D. et al., Nature 334:395-403, "T-cell antigen receptor genes and T-cell recognition". Aug. 4, 1988.
Barth et al., "The Murine T-Cell Receptor Uses A Limited Repertoire of Expressed V.beta. Gene Segments," Nature 316:517-523 (1985).
Ben-Nun et al., "The Rapid Isolation of Clonable Antigen-Specific T Lymphocyte Lines Capabhe of Mediating Autoimmune Encephalomyelitis," European Journal of Immunology 11:195-199 (1981).
Berzofsky, "T-Cell Activation by Antigen: Promising Clues to Reception Genes and Molecules," Immunology Today 4:299-301 (1983).
Clark et al., "Identification of a Diversity Segment of Human T-Cell Receptor .beta.-Chain, and Comparison with the Analogous Murine Element," Nature 311:387-389 (1984).
Clevers et al,. "The T-Cell Receptor/CD3 Complex: A Dynamic Protein Ensemble," Annual Review of Immunology 6:629-662 (1988).
Cohen and Weiner, "T-Cell Vaccination," Immunology Today 9:332-335 (1988).
Offner et al., "T Cell Receptor Peptide Therapy Triggers Autoregulation of Experimental Encephalomyelitis," Science 251:430-432 (1991).
Terasaki et al., "Multiple Sclerosis and High Incidence4 of a B Lymphocyte Antigen," Science 193:1245-1247 (1976).
Vandenbark et al., "TCR Peptide Therapy Decreases the Frequency of Encephalitogenic T Cells in the Periphery and the Central Nervous System," J. Neuroimmunology 39:251-260 (1992).
Vandenbark et al., "Human T Lymphocyte Response to Myelin Basic Protein: Selection of T Lymphocyte Lines from MPB-Responsive Donor," J. of Neuroscience Research 23:21-30 (1989).
Gaur et al., "Requirement of CD8+ Cells in T Cell Receptor Peptide-Induced Clonal Unresponsiveness", Science 259:91-93 (1993).
Karpus et al., "CD4+ Suppressor Cells of Autoimmune Encephalomyelitis Respond to T Cell Receptor-Associated Determinants on Effector Cells by Interleukin-4 Secretion", Eur. J. Immunol. 22:1757-1763 (1992).
Kumar et al., "The Involvement of T Cell Receptor Peptide-Specific Regulatory CD4+ T Cells in Recovery From Antigen-Induced Autoimmune Disease", J. Exp. Med. 178:909-916 (1993).
Stevens et al., "Studies of V.beta.8 T Cell Receptor Peptide Treatment in Experimental Autoimmune Encephalomyelitis" J. Neuroimmunol. 37:123-129 (1992).
Chou et al., "Immunity to TCR Peptides in Multiple Sclerosis", Amer. Assoc. of Immun., (1994) pp. 2520-2529.
Vainiene et al., "Common Sequence on Distinct Vbeta Genes Defines a Protective Idiotope in Experimental Encephalomyelitis", 31 Journal of Neuroscience Res. 413-420, 1992.
Cohen, "Regulation of Autoimmune Disease Physiological and Therapeutic", Immunological Reviews 1986, No. 94, pp. 5-21.
Katz et al., "The V-region disease hypothesis: evidence from autoimmune encephalomyelitis", Immunology Today, vol. 10(5): 164 (1989).
Bourdette et al., "Immunity to TCR Peptides in Multiple Sclerosis", Amer. Assoc. of Immun. (1994) pp. 2510-2519.
Kitzin et al., "Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis", 88 Proc. Nat'l Acad. Sci, USA 9161-9165, 1991.
Sakai, K. et al., Proc. Natl. Acad. Sci. USA 85: 8608-8612 (1988).
Wraith, D. C. et al., Cell 59:247-255 (1989).
Urban, J. L. et al., Cell 59: 257-271 (1989).
Kumar, V. et al., Ann. Rev. Immunol. 7:657-682 (1989).
Heber-Katz, E. et al., Immunol. Today 10:164-169 (1989).
Holoshitz, J. et al., J. Immunol. 131:2810-2813 (1983).
Cohen, I.R. Prog. Immunol. VI:491-499 (1986).
Lider, O. et al. Science 239:181-183 (1988).
Lider, O. et al., J. Autoimmun. 2:87-99 (1989).
Cohen, I. R. Hosp. Prac. pp. 57-64 (1989).
Sun, D. et al., Nature 332:843-845 (1988).
Sun, D. et al., Europ. J. Immunol. 18:1993-1999 (1988).
Chluba, J. et al., Europ. J. Immunol. 19:279-284 (1989).
Sun, D. et al., J. Immunol. 143:2867-2872 (1989).
Zamvil, S. et al., J. Exp. Med. 167:1586-1596 (1988).
Padula, S.J. et al., J. Clin. Invest. 81:1810-1818 (1988).
Beall, S.S. et al., J. Neuroimmunol. 21:59-66 (1989).
Brostoff,
Connective Therapeutics, Inc.
Cunningham Thomas M.
Lowin David A.
Warburg Richard J.
LandOfFree
T cell receptor peptides as therapeutics for immune-related dise does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with T cell receptor peptides as therapeutics for immune-related dise, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and T cell receptor peptides as therapeutics for immune-related dise will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2201086